Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
FoldRx (small-molecule therapeutics for protein misfolding diseases) raised $43mm in its Series B round that was led by Texas Pacific Group Ventures and Alta Partners. Novartis BioVenture Fund and existing investors HealthCare Ventures and Fidelity Biosciences also participated. The company will use the proceeds to continue clinical development of Fx1006A, its lead amyloid deposit inhibitor in Phase I trials to treat familial amyloid polyneuropathy and familial amyloid cardiomyopathy.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?